Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | BUB1 | O43683 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL899390 | 1.00 | USP2 (0.35) | USP2SMN1; SMN2MAPTBUB1KDM4E | |
| SCHEMBL899389 | 1.00 | USP2 (0.35) | USP2SMN1; SMN2MAPTBUB1KDM4E | |
| SCHEMBL898594 | 0.83 | — | — | |
| SCHEMBL898593 | 0.83 | — | — | |
| SCHEMBL14297529 | 0.79 | USP2 (0.43) | USP2SMN1; SMN2MAPTBUB1KDM4E | |
| SCHEMBL10211501 | 0.79 | MEN1 (0.44) | SMN1; SMN2MAPTKDM4ECCR5ALOX15 | |
| SCHEMBL899158 | 0.79 | MEN1 (0.44) | SMN1; SMN2MAPTKDM4ECCR5ALOX15 | |
| SCHEMBL899156 | 0.79 | MEN1 (0.44) | SMN1; SMN2MAPTKDM4ECCR5ALOX15 | |
| SCHEMBL12663837 | 0.78 | KDM4E (0.32) | KDM4E | |
| SCHEMBL21273181 | 0.74 | USP2 (0.40) | USP2SMN1; SMN2MAPTKDM4ETHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12472180-B2 | Combinations for treatment of NAFLD/NASH and related diseases | PFIZER INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-3972596-B1 | COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES | PFIZER (US) | 2025-07-16 | — | — | EP | disclosed |
| US-12247022-B2 | Combinations for treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2025-03-11 | — | — | US | disclosed |
| US-20230405002-A1 | COMBINATIONS OF DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS AND ACETYL-COA CARBOXYLASE INHIBITOR | PFIZER INC. (US) | 2023-12-21 | — | — | US | disclosed |
| US-20230322777-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230218616-A1 | Combinations for Treatment of NAFLD/NASH and Related Diseases | PFIZER INC. (US) | 2023-07-13 | — | — | US | disclosed |
| US-11673890-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2023-06-13 | — | — | US | disclosed |
| EP-3713942-B1 | CRYSTALLINE 2-AMINO-2-(HYDROXYMETHYL)PROPANE-1,3-DIOL SALT OF 4-(4-(1-ISOPROPYL-7-OXO-1,4,6,7-TETRAHYDROSPIRO[INDAZOLE-5,4'-PIPERIDINE]-1'-CARBONYL)-6-METHOXYPYRIDIN-2-YL)BENZOIC ACID | PFIZER (US) | 2023-03-08 | — | — | EP | disclosed |
| EP-4110394-A1 | COMBINATIONS OF DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS AND ACETYL-COA CARBOXYLASE INHIBITOR | Pfizer Inc. (US) | 2023-01-04 | — | — | EP | disclosed |
| US-20130296319-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. | 2013-11-07 | — | — | US | disclosed |
| US-8507681-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2621493-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | Pfizer Inc (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20130190334-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130030181-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER INC. (US) | 2013-01-31 | — | — | US | disclosed |
| US-8288405-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2499139-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | Pfizer Inc. (US) | 2012-09-19 | — | — | EP | disclosed |
| WO-2012042433-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2011058474-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| US-20110111046-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER INC | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190334-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | ACACA, ACACB, PC | USP2 2963/4885SMN1; SMN2 2809/4885MAPT 1882/4885 |
| US-20230322777-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, ACACB, PC | USP2 2735/4885SMN1; SMN2 2926/4885MAPT 1409/4885 |
| US-12247022-B2 | Combinations for treatment of NASH/NAFLD and related diseases | FABP1, PPARG, GOT2 | USP2 3963/4885SMN1; SMN2 2145/4885MAPT 3445/4885 |
| US-11673890-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | ACACA, ACACB, PC | USP2 2710/4885SMN1; SMN2 2884/4885MAPT 1417/4885 |
| US-20110111046-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, PC, ACACB | USP2 3415/4885SMN1; SMN2 3302/4885MAPT 1206/4885 |
| US-20130296319-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | ACACA, PC, ACACB | USP2 3301/4885SMN1; SMN2 3276/4885MAPT 1231/4885 |
| US-20230405002-A1 | COMBINATIONS OF DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS AND ACETYL-COA CARBOXYLASE INHIBITOR | ACAT2, ACACB, ACACA | USP2 2671/4885SMN1; SMN2 4425/4885MAPT 1666/4885 |
| US-20230218616-A1 | Combinations for Treatment of NAFLD/NASH and Related Diseases | FABP1, GOT2, CPT1A | USP2 4135/4885SMN1; SMN2 975/4885MAPT 2416/4885 |
| US-12472180-B2 | Combinations for treatment of NAFLD/NASH and related diseases | FABP1, GOT2, CPT1A | USP2 4135/4885SMN1; SMN2 975/4885MAPT 2416/4885 |
| US-20130030181-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, PC, ACACB | USP2 3415/4885SMN1; SMN2 3302/4885MAPT 1206/4885 |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | GLP1R, GCKR, GPR119 | USP2 3712/4885SMN1; SMN2 4180/4885MAPT 3530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.